Clinical Trials
Fulfilling the promise of genetic medicine
We are on a mission to make genetic medicines a reality for patients with cancer, autoimmune diseases, and other diseases with unmet needs. Inspired by frontline clinical need, we use rational design to create the genetic medicines of tomorrow.
Current clinical trials
INVISE: Injectable Vectors for In Situ Engineering
Talk to your physician if you are interested in a clinical trial.
Our phase 1 clinical trial for INT2104 is open and enrolling participants. The purpose of this first-in-human study is to evaluate the safety of a single INT2104 infusion when administered to participants with refractory or relapsing B-cell malignancies. Preliminary efficacy information may also be obtained from this study.
Expanded access policy
We are developing targeted, programmable vectors for the precise delivery of genetic medicines to address an array of challenging diseases. Our goal is to bring genetic medicine to all patients to treat diseases in oncology, autoimmunity, and other indications with unmet needs. On our journey to broaden patient use, the drugs we develop undergo rigorous research design, preclinical testing, and clinical assessment in multiple clinical trials. During clinical trials, the investigational treatments are evaluated for safety and effectiveness in relevant populations of human clinical trial participants.
Participation in clinical trials occurs at open clinical trial sites, where medical and other hospital personnel have been trained to administer the investigational product and care for the participants. Participants are enrolled after meeting the inclusion criteria established by the clinical trial protocol.
Occasionally, we receive inquiries about treatment with investigational products outside of this process on an emergency “expanded access” basis. Currently, we do not make investigational medicine available outside of clinical trials. We are just beginning to study our investigational products in the clinic and do not have sufficient data for their safety and efficacy to support expanded access. Once we have collected a sufficient body of clinical data, we will develop a process for evaluating expanded access requests.